Black Health
Atypical opioid; CYP2D6-activated mu-opioid agonist plus SNRI Moderate to moderately severe pain

Tramadol (Ultram, ConZip, Ultracet (with acetaminophen)) and Black patients

Brand names: Ultram, ConZip, Ultracet (with acetaminophen)

Last reviewed: Sources checked:

What Tramadol does

Tramadol is a weak mu-opioid agonist that also inhibits serotonin and norepinephrine reuptake. A portion of its analgesic effect comes from its CYP2D6-produced active metabolite O-desmethyltramadol (M1), which is a stronger opioid than tramadol itself.

What the evidence says for Black patients

Tramadol has the most race-relevant pharmacogenomic profile of any common analgesic, and the most problematic equity implications:

  • CYP2D6 metabolism. CYP2D6 poor metabolizers convert tramadol to its active metabolite at very low rates — meaning they get little analgesia from a standard dose. CYP2D6 ultra-rapid metabolizers convert tramadol extremely quickly and can develop life-threatening opioid toxicity at standard doses (the same mechanism that caused pediatric deaths from codeine; FDA boxed warning).
  • CYP2D6 allele distributions differ by ancestry. Black populations show a modestly higher frequency of poor-metabolizer alleles, contributing to variable analgesic response. Ultra-rapid metabolism is more common in populations with North African and Ethiopian ancestry.
  • FDA 2017 boxed warning extends the pediatric codeine warning to tramadol: contraindicated in children under 12 and after tonsillectomy in children under 18 because of unpredictable metabolism.
  • Clinician attitudes. Tramadol is sometimes prescribed in lieu of a stronger, more predictable opioid specifically to Black patients, based on the misperception that it is 'not a real opioid.' This both leaves pain under-treated and exposes patients to the serotonergic, seizure, and pharmacogenomic risks of tramadol without adequate benefit. An honest conversation about whether hydrocodone, morphine, or oxycodone would be more appropriate is often warranted.
  • Tramadol is a Schedule IV controlled substance. DEA scheduling adds surveillance burden that affects Black patients disproportionately.

Common alternatives

Acetaminophen + NSAID combination for mild-to-moderate pain. Hydrocodone-acetaminophen, oxycodone, or morphine for moderate-to-severe pain with more predictable pharmacokinetics. Topical lidocaine or capsaicin. Duloxetine for chronic musculoskeletal pain.

Side effects

  • Opioid side effects — constipation, nausea, sedation, respiratory depression
  • Seizure risk — especially with SSRI/SNRI, bupropion, or at high doses
  • Serotonin syndrome with SSRIs/SNRIs/MAOIs
  • Dependency and withdrawal
  • Unpredictable potency based on genotype

Factors that affect adherence

Do not combine with SSRIs, SNRIs, or bupropion without explicit clinician guidance. Do not combine with alcohol. Report inadequate pain control — it may mean you are a CYP2D6 poor metabolizer and need a different opioid entirely.

Questions to ask your doctor

Bring this list to your next appointment.

  • Is tramadol specifically the right choice, or is it being chosen because I'm Black and you're uncomfortable prescribing a stronger opioid?
  • If this isn't controlling my pain, what do we try next?
  • Am I taking any serotonergic drugs that interact?
  • If I have seizure risk factors, is this safe for me?

References

  1. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95:376–382.
  2. Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations. PNAS. 2016;113:4296–4301.
  3. U.S. Food and Drug Administration. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children. 2017-04-20. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-restricts-use-prescription-codeine-pain-and-cough-medicines-and
  4. U.S. Food and Drug Administration. Ultram (tramadol hydrochloride) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020281s032s033lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.